NASDAQ$OLMA
Olema Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Olema Oncology reported third quarter financial results and provided a corporate update.
Olema Oncology reported a net loss of $22.7 million for the third quarter of 2022. As of September 30, 2022, the company's cash, cash equivalents, and marketable securities totaled $222.6 million, expected to fund operations into the second half of 2024. The company is advancing its OP-1250 clinical development program and combination studies.
- Presented preliminary results from OP-1250 Phase 1/2 dose expansion study demonstrating favorable tolerability, high drug exposure, and strong anti-tumor activity.
- Initial clinical data for OP-1250 in combination with palbociclib to be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).
- First pivotal monotherapy Phase 3 study initiation planned for mid-2023.
- Cash, cash equivalents and marketable securities totaled $222.6 million as of September 30, 2022, sufficient to support execution of clinical, research and operational goals into the second half of 2024.
Headline financials
Revenue & EPS history
Olema · Revenue · Quarterly
$0
Forward guidance
Olema Oncology anticipates presenting preliminary Phase 1b data for OP-1250 with palbociclib at SABCS in December 2022, continuing combination studies, presenting additional monotherapy and combination therapy data in 2023, and initiating a pivotal Phase 3 monotherapy study in mid-2023.
Tailwinds
- Present preliminary Phase 1b dose escalation study data in combination with CDK4/6 inhibitor, palbociclib, at the 2022 San Antonio Breast Cancer Symposium in December.
- Continue combination studies with CDK4/6 inhibitors, palbociclib and ribociclib, and PI3Ka inhibitor, alpelisib.
- Present additional monotherapy and combination therapy data in 2023.
- Initiate pivotal Phase 3 monotherapy study in the second/third-line ER+/HER2- advanced or metastatic breast cancer in mid-2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-0.1%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+7.5%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+17.0%
Q4 2021
Best reaction
-28.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.2% | -7.7% | -29.4% | |
| Q3 2025 | +4.1% | +0.6% | +267.4% | |
| Q2 2025 | +16.0% | +20.6% | +75.1% | |
| Q1 2025 | +2.1% | +9.6% | -11.0% | |
| Q4 2024 | -8.5% | +4.3% | +6.8% | |
| Q3 2024 | -9.7% | -27.9% | -47.2% | |
| Q1 2024 | -12.5% | -18.0% | +16.8% | |
| Q4 2023 | -6.6% | -11.2% | -15.8% | |
| Q3 2023 | -7.6% | -7.4% | -29.2% | |
| Q2 2023 | +15.3% | +14.0% | +24.7% | |
| Q1 2023 | +1.1% | +6.1% | -0.3% | |
| Q4 2022 | +0.0% | +0.3% | -15.4% | |
| Q3 2022 | -7.2% | +5.6% | -22.5% | |
| Q2 2022 | -28.5% | -29.4% | -23.1% | |
| Q1 2022 | -1.3% | -3.1% | +79.4% | |
| Q4 2019 | +17.0% | -2.2% | -5.9% | |
| Q4 2021 | +17.0% | -2.2% | -5.9% | |
| Q3 2021 | +1.1% | -1.9% | -61.9% | |
| Q3 2020 | +1.1% | -1.9% | -61.9% | |
| Q2 2020 | +3.4% | +1.9% | +11.2% | |
| Q2 2021 | +3.4% | +1.9% | +11.2% | |
| Q1 2021 | +11.9% | +14.8% | +35.8% | |
| Q4 2020 | -10.2% | -23.2% | -27.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro